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O R I G I N A L  R E S E A R C H
Abstract: Peripheral benzodiazepine (BDZ) receptors were investigated by means of the
binding of the specific ligand 3H-PK 11195 to platelet membranes in patients suffering from
bipolar disorder and in healthy controls. The results showed that the density (Bmax) of
peripheral BDZ receptors was significantly higher in patients than in control subjects, with no
change in the dissociation constant. No correlation with demographic or clinical features was
observed. These findings would suggest that alterations of peripheral BDZ receptors are present
in patients suffering from bipolar disorder, but it is premature to conclude whether they may
be related to the pathophysiology of the disorder, or are secondary to changes occurring in
other systems, such as those regulating the stress response.
Keywords: benzodiazepine receptors, peripheral benzodiazepine receptors, mitochondria,
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Introduction
Several types of high-affinity binding sites for benzodiazepines (BDZ) have been
described in the central nervous system (CNS) and in peripheral organs on the basis
of their different affinity for radiolabeled ligands (Mohler and Okada 1977; Olsen
and Venter 1986). The central receptors, almost all of which are found in the cortex,
limbic areas, and cerebellum (Young and Kuhar 1979), are mainly labeled by
flumazenil, whereas the peripheral type of BDZ receptors are identified specifically
by Ro 5-4864 and PK 11195 (Marangos et al 1982). The most abundant sources of
peripheral BDZ receptors are kidneys, lungs, ovaries, testes, and adrenal glands, but
they are also present in the CNS, particularly in glial cells (Anholt et al 1984).
From a functional point of view, while the salient feature of the central BDZ
receptor is coupling with the GABA-A receptor complex and facilitation of GABA
transmission (Costa et al 1978), the peripheral type lacks this association and is
localized to the mitochondrial outer membrane (Anholt et al 1986; Sprengel et al
1989). The most exhaustive hypothesis on the role of this receptor is the one suggesting
a role in steroidogenesis, since in adrenals it has been demonstrated that it mediates
the translocation of cholesterol from the outer to the inner mitochondrial membrane
and is involved in the chain cleavage of cholesterol (Muhkin et al 1989; Papadopoulos
et al 1990). Therefore, it is supposed that peripheral BDZ receptors subserve the
same function in nonsteroidogenic tissues; particularly in glial cells, which have
been shown to synthetize steroids, such as pregnenolone and progesterone and its
derivatives called neurosteroids, which are able to alter the electrical properties of
neuronal membranes and thus the firing patterns of neurons (Anholt et al 1986; Hu
et al 1989; Jung-Testas et al 1989; Wodarz et al 1998). Such compounds, in turn,















Biotecnologie, University of Pisa,
via Roma, 67, I-56100 Pisa, Italy
Tel +39 050 835 412
Fax +39 050 21581
Email dmarazzi@psico.med.unipi.it
Changes in peripheral benzodiazepine
receptors in patients with bipolar disorder
Neuropsychiatric Disease and Treatment 2005:1(2)152
Marazziti et al
(Purdy et al 1990). It is noteworthy that different stress
paradigms in animals produce changes in peripheral BDZ
receptors (Drugan et al 1986, 1987; Okun et al 1988).
Furthermore, the peripheral BDZ receptor is involved
in a variety of other actions, such as control of cell
proliferation, chemiotaxis, and contractility of the
myocardium (Ruff et al 1985; Lenfant 1989; Taupin et al
1991; Ferrarese et al 1993).
The presence of these receptors in blood cells, such as
platelets or lymphocytes, which undergo the same regulation
and changes as in other tissues, particularly in the brain
(Drugan et al 1986), has offered a peripheral tool for studies
in humans. Stressful situations, such as sitting an exam (Karp
et al 1989) or a parachute-training course (Dar et al 1991),
influence the density of receptors as an acute stress seems
to provoke an up-regulation, while a repeated stress provokes
a down-regulation (Drugan et al 1987; Okun et al 1988; Hu
et al 1989; Jung-Testas et al 1989; Purdy et al 1990).
The literature is also reporting changes of peripheral
BDZ receptors in different psychiatric disorders, such as
generalized anxiety disorder (GAD), social phobia, panic
disorder, obsessive-compulsive disorder (OCD), Alzheimer’s
disease, and schizophrenia (Gavish et al 1986; Bonuccelli
et al 1991; Rocca et al 1991; Marazziti, Rotondo, et al 1994;
Bidder et al 1997), while no information is available in
patients with mood disorders, in spite of evidence that stress
systems are altered in these diseases (for review, see Claes
2004), and there is frequent comorbidity with various
anxiety disorders (Chen and Dilsaver 1995; Goodwin and
Hoven 2002; Simon et al 2004).
To further clarify this issue, we investigated peripheral
BDZ receptors by the specific binding of 3H-PK 11195 in
platelets of patients suffering from bipolar disorder,
according to strict DSM-IV criteria, and in a similar group
of healthy control subjects.
Subjects and methods
Subjects
Twenty outpatients (12 male and 8 female, between 23 and
55 years of age, mean ± SD: 35.7 ± 11.4) affected by bipolar
disorder were included in the study. Diagnoses were made
by trained psychiatrists according to the Structured Clinical
Interview (SCID) for DSM-IV (APA 1994; First et al 1997).
Twelve patients were bipolar II (5 were depressed, 7
euthymic) and 8 were bipolar I (all in the euthymic phase).
Five patients out of the total 20 were drug-free and fifteen
were taking mood stabilizers (5 lithium salts, 8 valproate, 1
gabapentin, 1 lamotrigine). Of the total 5 depressed patients,
3 were taking antidepressants (1 clomipramine, 1 sertraline,
2 citalopram, 1 fluvoxamine), drugs that do not interfere
with 3H-PK 11195 binding parameters. No patient was
taking BDZs.
The controls included 20 healthy drug-free subjects (10
male and 10 female, between 25 and 45 years of age,
mean ± SD: 28.6 ± 5.4), with neither family nor personal
history of any major psychiatric disorder, as recorded by
the SCID.
In addition, both patients and controls had no physical
illness, as documented by a physical exam and blood and
urine tests. Informed consent was obtained from all subjects
of the study, which was approved by the Ethics Committee
at Pisa University.
Methods
Thirty milliliters of venous blood was drawn from fasting
subjects between 8 am and 10 am, collected into plastic tubes
containing 5 mL of anticoagulant (2.2% sodium citrate and
1.2% citric acid), and centrifuged at 150 × g for 15 min at
23 °C. Platelet-rich-plasma was collected and centrifuged
at 1500 × g for 15 min at 23 °C. The drained platelet pellet
was frozen at –80 °C until the binding assay, which was
carried out within 2 weeks. Prior to the binding assay, the
platelets were lysed and homogenized in 12 mL buffer
(50 mmol/L Tris HCl, pH 7.4) using an Ultra Thurrax
homogenizer for 5 s at 2/3 full speed and then centrifuged
at 49 000 × g for 15 min at 4 °C. This procedure was im-
mediately repeated. The membranes were resuspended in
12 mL of 50 mmol/L tris HCl and used for binding studies.
The binding of 3H-PK 11195 to platelet membranes was
performed according to a slight modification of the method
of Gavish et al (1986). Four hundred microliters  of
membrane suspension (50 µg protein) was incubated with
20 µL of PK 11195 (specific activity: 82.4 Ci/mmol NEN,
England,) at final concentrations ranging between 1 and
8 nmol/L, and 50 mmol/L Tris HCl buffer, pH 7.4, in a total
volume of 500 µL. Non-specific binding was determined in
the presence of 10 µmol/L unlabelled PK 11195 (Sigma,
Milan, Italy). The incubation lasted for 90 min at 0 °C and
was stopped by the addition of 5 mL of ice-cold incubation
buffer and filtration under vacuum over Whatman GF/B
filters. The filters were washed three times with 5 mL of the
same buffer, placed in vials and counted in 4 mL of
scintillation cocktail in a liquid scintillation counter.
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The data were evaluated by Scatchard analysis to obtain
the maximal number of binding sites (Bmax, fmol/mg
protein) and their affinity to 3H-PK 11195 as expressed by
the equilibrium dissociation constant (Kd, nmol/L), by
means of microcomputer programs (EBDA and LIGAND)
(McPhearson 1985).
Protein concentration was determined according to the
method of Peterson (1977). The difference between the
groups was measured by means of Student’s test (un-paired,
two-tailed). The effect of age and sex on biological
parameters was assessed by means of covariance analysis,
and the possible correlations between biological findings
and psychopathological data were analyzed according to
Pearson’s method, with Personal Computer programs
(StatView V, SSPS) (Nie et al 1998).
Results
The results showed that the Bmax (mean ± SD, fmol/mg
protein) was 6263 ± 1960 in bipolar disorder patients and
4855 ± 1621 in the control subjects, statistically higher in
the first than in the other group (t-test: p < 0.01). On the
contrary, the Kd (mean ± SD, nmol/L) did not show any
difference, with the values 5.43 ± 1.53 in the patients and
5.33 ± 1.92 in the control subjects. No difference between
patients with bipolar I and bipolar II disorder was detected.
No age or sex effect was observed, and no relationship
between biological parameters and clinical features was
noticed.
Discussion
The major finding of this study is the presence of an
increased density (Bmax) of peripheral BDZ receptors in
platelets of patients with bipolar disorder, as compared with
healthy controls, with no associate change in the dissociation
constant. No difference between bipolar I and bipolar II
patients was detected. Since a significant increase in Kd
values has been reported in subjects over 70 years of age
(Marazziti, Pancioli, et al 1994), we controlled this variable
in the groups who were selected on the basis of a limited
age range, and we observed no effect. Similarly, no sex-
related influence on the binding of 3H-PK-11195 was
noticed. Although no seasonal change in the binding has
been observed to date, we performed all the blood sample
analysis in a limited period of the year (from March to May).
Our results in patients with bipolar disorder are the first
report in this group of patients; however, it must be
mentioned that due to the small sample size it was not
possible to perform reliable statistical analyses or to ascertain
the real impact, if any, of the different phases of the illness
on 3H-PK 11195 binding.
Previously, patients with panic disorder, social phobia,
or GAD have been shown to have a low density of PK11195
binding sites (Weizman et al 1987; Ferrarese et al 1990;
Johnson et al 1998). In addition, in patients with GAD, the
density of peripheral BDZ receptors would return towards
the values found in healthy controls after treatments with
BDZs (Ferrarese et al 1990). With regard to patients with
OCD, the ensuing findings are quite controversial: patients
with a chronic course seem to be characterized by no change
in the binding of 3H-PK11195 (Marazziti, Rotondo, et al
1994), while patients with an episodic course would show a
decreased density of 3H-PK11195 binding sites (Rocca et
al 1991). In some cases, decreased peripheral BDZ receptor
density in lymphocytes has been showed to be paralleled
by similar changes in mRNA levels (Rocca et al 1991;
Nudmamud et al 2000).
The modifications observed in platelets should reflect
similar changes in other organs rich in peripheral BDZ
receptors, such as glial cells and pituitary at the level of the
CNS, heart, and kidney, as it has been demonstrated in rats
that underwent inescapable tail shock (Drugan et al 1986).
Such changes might be linked with a general membrane
abnormality, as it has been proposed for Alzheimer’s
dementia (Zubenko et al 1987), or with abnormalities in
endogenous ligands acting at their level, or represent a non-
specific sign of stress, as it has been demonstrated that
peripheral BDZ receptor density is significantly correlated with
changes in corticosteroid levels (Nudmamud et al 2000).
In any case, it is puzzling that bipolar patients with no
comorbid disorder have an increased density of peripheral
BDZ receptors, at variance with patients with other
psychiatric conditions, mainly of the anxiety spectrum. It is
not possible as yet to conclude whether the changes in
peripheral BDZ receptors represent a primary phenomenon
related to the etiology or pathophysiology of the disease, or
alternatively are secondary to changes in other systems, such
as those regulating the stress response.
Future studies should aim to explore peripheral BDZ
receptors in patients with other mood disorders with and
without comorbid conditions in order to clarify whether
eventual changes at their level might be helpful in confirming
diagnostic categories or in characterizing different
comorbidity patterns.
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